Close

Viral Infection

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Besides various cancers, Creative Biolabs also provides customer with CellRapeutic™ Chimeric Antigen Receptor (CAR) products targeting viral antigens and viral-associated cancer antigens. Here, we now offer customer cutting edge CAR-T products targeting a range of viral antigens arising from Epstein–Barr virus (EBV), Cytomegalovirus (CMV), and Adenovirus (Adv).

The EBV, also known as human herpesvirus 4 (HHV-4), is one of the eight viruses in herpes family, and is one of the most common viruses in human. Infection with EBV is associated with several cancers like Hodgkin's lymphoma, Burkitt's lymphoma, gastric cancer, nasopharyngeal carcinoma, and certain autoimmune diseases such as dermatomyositis, systemic lupus erythematosus, rheumatoid arthritis, Sjögren's syndrome and multiple sclerosis. The Cytomegalovirus (CMV), also known as human herpesvirus-5 (HHV-5), is a kind of viruses in the Herpesviridae family. CMV infection is a common incident that can affect any people. There's no efficient treatment for CMV, however, compounds can help treat newborns and individuals with weak immune systems.

Products ordering information

If you need any information, please don't hesitate to contact with us at anytime.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.